Potential therapeutic effects of antagonizing adenosine A2A receptor, curcumin and niacin in rotenone-induced Parkinson’s disease mice model

Motawi, Tarek K.; Sadik, Nermin Abdel Hamid; Hamed, Manal A.; Ali, Sanaa A.; Khalil, Wagdy K. B.; Ahmed, Yomna R.

doi:10.1007/s11010-019-03670-0

Cited by 49 publications

(18 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This yellow pigmented powder is derived from rhizome of turmeric via grinding [22]. It is responsible for the yellow color of turmeric and for a long time, this flavoring substance has been widely applied in different regions of Asia for treatment of various disorders [23][24][25][26]. The chemical formula of curcumin is n,1,7-bis-(3-hydroxy-4-methoxyphenyl)-1,6-heptadiene-3,5-dione.…”

Section: Curcumin: Structure and Pharmacokineticsmentioning

confidence: 99%

Polychemotherapy with Curcumin and Doxorubicin via Biological Nanoplatforms: Enhancing Antitumor Activity

et al. 2020

View full text Add to dashboard Cite

Doxorubicin (DOX) is a well-known chemotherapeutic agent extensively applied in the field of cancer therapy. However, similar to other chemotherapeutic agents such as cisplatin, paclitaxel, docetaxel, etoposide and oxaliplatin, cancer cells are able to obtain chemoresistance that limits DOX efficacy. In respect to dose-dependent side effect of DOX, enhancing its dosage is not recommended for effective cancer chemotherapy. Therefore, different strategies have been considered for reversing DOX resistance and diminishing its side effects. Phytochemical are potential candidates in this case due to their great pharmacological activities. Curcumin is a potential antitumor phytochemical isolated from Curcuma longa with capacity of suppressing cancer metastasis and proliferation and affecting molecular pathways. Experiments have demonstrated the potential of curcumin for inhibiting chemoresistance by downregulating oncogene pathways such as MMP-2, TGF-β, EMT, PI3K/Akt, NF-κB and AP-1. Furthermore, coadministration of curcumin and DOX potentiates apoptosis induction in cancer cells. In light of this, nanoplatforms have been employed for codelivery of curcumin and DOX. This results in promoting the bioavailability and internalization of the aforementioned active compounds in cancer cells and, consequently, enhancing their antitumor activity. Noteworthy, curcumin has been applied for reducing adverse effects of DOX on normal cells and tissues via reducing inflammation, oxidative stress and apoptosis. The current review highlights the anticancer mechanism, side effects and codelivery of curcumin and DOX via nanovehicles.

show abstract

Section: Curcumin: Structure and Pharmacokineticsmentioning

confidence: 99%

Polychemotherapy with Curcumin and Doxorubicin via Biological Nanoplatforms: Enhancing Antitumor Activity

et al. 2020

View full text Add to dashboard Cite

show abstract

“…This issue needs to be clarified in future research. Considering the pleotropic effect of curcumin on neurodegenerative diseases, cancers and immune disorders, curcumin is a promising substance for treating disease today without causal treatment [1,2,10,[51][52][53][54][55][56][57]. In addition, it is a safe, inexpensive substance, easily accessible and penetrates the blood-brain barrier and neuronal membranes, which is its great advantage [1][2][3]7].…”

Section: Discussionmentioning

confidence: 99%

Mutual Two-Way Interactions of Curcumin and Gut Microbiota

Pluta

Januszewski

Ułamek-Kozioł

2020

IJMS

View full text Add to dashboard Cite

Curcumin, an herbal naturally occurring polyphenol, has recently been proposed for the treatment of neurodegenerative, neurological and cancer diseases due to its pleiotropic effect. Recent studies indicated that dysbiosis is associated with the abovementioned and other diseases, and gut microflora may be a new potential therapeutic target. The new working hypothesis that could explain the curative role of curcumin, despite its limited availability, is that curcumin acts indirectly on the brain, affecting the “gut–brain–microflora axis”, a complex two-way system in which the gut microbiome and its composition, are factors that preserve and determine brain health. It is therefore suspected that curcumin and its metabolites have a direct regulatory effect on gut microflora and vice versa, which may explain the paradox between curcumin’s poor bioavailability and its commonly reported therapeutic effects. Curcumin and its metabolites can have health benefits by eliminating intestinal microflora dysbiosis. In addition, curcumin undergoes enzymatic modifications by bacteria, forming pharmacologically more active metabolites than their parent, curcumin. In this review, we summarize a number of studies that highlight the interaction between curcumin and gut microbiota and vice versa, and we consider the possibility of microbiome-targeted therapies using curcumin, particularly in disease entities currently without causal treatment.

show abstract

“…One of the more interesting, but still relatively unknown, mechanisms of curcumin is related to αsynuclein aggregation/disaggregation and oligomer-induced toxicity in dopaminergic neurons, which may prevent Lewy Bodies accumulation. Curcumin inhibited the α-synuclein aggregation in rodents treated with LPS or rotenone, through inhibition of oxidative stress generation, replenishing GSH levels, as well as preventing the inflammatory response (276,278). Curcumin efficiently prevented C o p y r i g h t E d r a S .…”

Section: Parkinson Diseasementioning

confidence: 99%

The pharmacological basis of the curcumin nutraceutical uses: an update

Canistro¹,

Chiavaroli²,

Cicia³

et al. 2021

Pharm Adv

View full text Add to dashboard Cite

Curcumin is the major phytoconstituent found in the rhizomes of Curcuma longa L. Preparations derived from the rhizome of the plant, referred as turmeric, have been used for centuries in the traditional Indian system of medicine. The recent literature has shown curcumin as one of the most interesting pleiotropic nutraceuticals capable of interacting with different molecular targets involved in chronic diseases. The present review summarizes and critically discusses the very recent literature published between 2018 and 2021. We focused on the preclinical pharmacological actions of curcumin in relation to its possible clinical application in several pathophysiological states and disturbances including inflammation and pain, as well as metabolic, cardiovascular, dermatological, and central nervous system diseases. The most relevant molecular targets of curcumin, such as transcription factors, pro-inflammatory mediators, enzymes, and protein kinase as well as pharmacokinetics in humans are also reviewed.

show abstract

Potential therapeutic effects of antagonizing adenosine A2A receptor, curcumin and niacin in rotenone-induced Parkinson’s disease mice model

Cited by 49 publications

References 77 publications

Polychemotherapy with Curcumin and Doxorubicin via Biological Nanoplatforms: Enhancing Antitumor Activity

Polychemotherapy with Curcumin and Doxorubicin via Biological Nanoplatforms: Enhancing Antitumor Activity

Mutual Two-Way Interactions of Curcumin and Gut Microbiota

The pharmacological basis of the curcumin nutraceutical uses: an update

Contact Info

Product

Resources

About